Somewhat Positive Press Coverage Somewhat Unlikely to Impact Repligen (RGEN) Stock Price

News stories about Repligen (NASDAQ:RGEN) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Repligen earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.1150396402817 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:

RGEN has been the topic of a number of recent analyst reports. Jefferies Group reaffirmed a “hold” rating and set a $40.00 price target on shares of Repligen in a report on Thursday, September 14th. CL King initiated coverage on shares of Repligen in a report on Monday, November 13th. They set a “buy” rating and a $41.00 price target on the stock. Zacks Investment Research raised shares of Repligen from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a report on Thursday, October 5th. TheStreet downgraded shares of Repligen from a “b-” rating to a “c” rating in a report on Monday, November 13th. Finally, Citigroup initiated coverage on shares of Repligen in a report on Friday, December 8th. They set a “buy” rating and a $45.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $44.38.

Shares of Repligen (NASDAQ RGEN) opened at $35.44 on Friday. Repligen has a one year low of $28.48 and a one year high of $46.81. The company has a market cap of $1,540.00, a P/E ratio of 60.91, a price-to-earnings-growth ratio of 2.30 and a beta of 1.04.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.04. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The company had revenue of $36.58 million for the quarter, compared to analysts’ expectations of $35.69 million. During the same quarter last year, the business earned $0.08 EPS. The firm’s revenue was up 48.2% compared to the same quarter last year. equities analysts forecast that Repligen will post 0.61 earnings per share for the current year.

In other Repligen news, VP Howard Benjamin sold 12,729 shares of the stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $35.34, for a total transaction of $449,842.86. Following the completion of the sale, the vice president now directly owns 36,554 shares of the company’s stock, valued at approximately $1,291,818.36. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at

About Repligen

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit